Epic Sciences Enters into Collaboration with Q2 Solutions to Expand Liquid Biopsy Capabilities
Epic Sciences, Inc. today announced it has entered into a global collaboration with Q2 Solutions®, a leading clinical trial laboratory services organization,to offer Illumina®’s TruSight Oncology 500 liquid biopsy test to Epic’s global biopharmaceutical customers. The addition of TruSight Oncology 500 to Epic’s portfolio of testing capabilities, brings ctDNA analysis to Epic’s CTC-based platform that enumerates and characterizes circulating tumor cells (CTCs). TruSight Oncology 500 enables analysis of circulating tumor DNA (ctDNA) of the full exonic sequence of over 500 genes in key cancer-related pathways, and includes identifying single-nucleotide variants, indels, copy number variants, DNA fusions, microsatellite instability (MSI) and tumor mutational burden (TMB). Read Full Release
Epic Sciences to Present Multiple Abstracts at ASCO 2020 Highlighting the Importance of CTCs in Liquid Biopsy
Epic Sciences, Inc. today announced that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held from May 29 – June 2, 2020. Epic Sciences will present new data demonstrating the role of circulating tumor cells (CTCs) in cancer prognosis and treatment outcomes. Read Full Release
Epic Sciences to Present New Data Demonstrating Expanded Clinical Utility of AR-V7 at 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium
Epic Sciences, Inc. announced today it will present two abstracts at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium to be held in San Francisco, February 13 – 15, 2020. The abstracts feature two analyses of the PROPHECY trial cohort. One abstract evaluates the androgen-receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) as a predictor of resistance to anti-androgen therapy. The second abstract reports new data on CTC-based biomarkers of chromosomal instability and small-cell neuroendocrine transformation and their association to resistance to anti-androgen therapy. Read Full Release
Epic Sciences to Present New Data Showing Feasibility of its Liquid Biopsy Test in Breast Cancer
Epic Sciences, Inc. today announced the presentation of new data demonstrating the feasibility of using its proprietary technology for the detection and characterization of rare cells to guide the treatment of breast cancer. The data to be presented show the use of Epic Sciences’ liquid biopsy test to profile circulating tumor cells (CTCs) based on morphological features, protein marker expression and genomic alterations. Epic Sciences will present the data at the 2019 San Antonio Breast Cancer Symposium held on December 10 – 14, in San Antonio, Texas. Read Full Release


05.28.2020 | Clinical OMICs
Comprehensive Approach - Epic Sciences has retooled its management team and is combining CTC and ctDNA technologies in its pursuit of comprehensive cancer profiling.
In the realm of liquid biopsy as a tool for precision medicine and the different cells and fractions that can be collected from a standard blood draw, there has always been a sense that there is something missing. Circulating tumor cells (CTCs,) hard to collect, and even harder to collect as a viable cell, would never be the source of all the information needed to make a targeted cancer diagnosis. Read Full Article
02.25.2020 | OncLive
Dr. Armstrong on the Rationale of the PROPHECY Trial in mCRPC
Andrew J. Armstrong, MD, professor of medicine, associate professor in pharmacology and cancer biology, and professor in surgery at Duke University School of Medicine and a member of the Duke Cancer Institute, discusses the rationale of the PROPHECY trial in metastatic castration-resistant prostate cancer (mCRPC). Read Full Article
01.15.2020 | genomeweb
Circulating Tumor Cell Collection, Analysis Methods Make Headway in 2019
NEW YORK – 2019 was a busy year for circulating tumor cell (CTC) capture and detection, as academic and commercial groups continued to develop novel techniques to extract and purify CTCs for diagnosing several cancers, and accelerated their efforts to bring these technologies to the clinic. Notably, companies are increasingly exploring CTC capture methods alongside circulating tumor DNA (ctDNA) purification and analysis tools to distinguish themselves from the crowded ctDNA detection space and potentially unlock additional liquid biopsy applications. Read Full Article
12.27.2019 | Fierce Biotech
Blood Testing Nears a Turning Point as the Evidence Becomes Undeniable
Blood has always held the keys to our bodies’ health: it helps carry nutrients in and waste out, and interrogating it can provide solace when we are well and answers when we are sick. Blood testing is ubiquitous, but it’s clear its possibilities are unfulfilled. Through different methods and modalities, these diagnostics promise to be a more accessible, less invasive, smarter, cheaper and a comprehensive way to gather knowledge about what’s going on under the skin—whether in a doctor’s office, at home or within a clinical laboratory. Read Full Article


ASCO 2020
The Epic Sciences team will be presenting at the virtual ASCO 2020 Annual Meeting - From May 29 - 31, 2020. More Info
SABCS 2019
The Epic Sciences team will be attending and exhibiting at the San Antonio Breast Cancer Symposium - Booth #626 - in San Antonio, TX from December 10 - December 14, 2019. More Info
ASCO 2019
The Epic Sciences team will be attending ASCO 2019 Annual Meeting - Booth #2066 - in Chicago, IL from May 31 - June 4, 2019. More Info
AACR 2019
The Epic Sciences team attended AACR Annual Meeting - Booth #4455 - in Atlanta, GA from March 29 - April 3, 2019. More Info